Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women

NCT07349641 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07349641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07349641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
October 31, 2030
Enrollment
55 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia, figo grade 1 endometrial endometrioid adenocarcinoma